D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors

Cancers that are sensitive to EGFR inhibitors downregulate Phosphoinositide 3-Kinase (PI3K) signaling in response to these drugs. Inhibition of PI3K signaling appears to be critical for ErbB inhibitors to induce cell death. Although lung cancers with EGFR mutation often have initial impressive responses to EGFR inhibitors, they invariably develop resistance. In 50% of such patients, a single secondary mutation, a substitution of methionine for...